Retatrutide
Triple agonist of GLP-1, GIP and glucagon receptors — the newest generation of metabolic peptides.
Retatrutide is the most complex molecule in metabolic research to date: it activates three receptor pathways at once (GLP-1, GIP and the glucagon receptor), where older compounds worked with one or two.
In a Phase 2 trial published in the New England Journal of Medicine, participants on the highest dose lost an average of 24.2 % of body weight over 48 weeks — and were still losing when the trial ended. Studied in the context of energy expenditure, lipolysis and satiety regulation.
View product →
Tirzepatide
Dual GIP and GLP-1 agonist — the generation before Retatrutide.
Tirzepatide combines two incretin pathways: GLP-1 and GIP. In metabolic research this dual combination proved markedly more effective than a GLP-1 agonist alone.
In year-long trials average weight reduction was around 21 %, compared with roughly 15 % for single GLP-1 agonists. Studied for its effect on glycaemic control and body composition.
View product →
Semaglutide
Single GLP-1 receptor agonist — the compound that opened up the whole category.
Semaglutide acts on a single pathway, the GLP-1 receptor. It slows gastric emptying, influences central food-intake signalling and stimulates insulin release in response to meals.
Historically it is the compound that brought metabolic peptide research into wide awareness. Newer dual and triple agonists outperform it on outcomes, but it remains the best-documented molecule in the category.
We do not currently stock this compound.
AOD-9604
A growth hormone fragment isolated purely for its lipolytic action.
AOD-9604 is a 16-amino-acid fragment from the tail of the growth hormone molecule. Researchers at Monash University isolated it to separate hGH's fat-metabolising activity from its effects on blood sugar and cell growth.
Preclinical studies in Hormone Research and the American Journal of Physiology showed stimulated lipolysis and inhibited fat storage in animal models, without the insulin resistance associated with full-length growth hormone.
View product →
HGH Fragment 176-191
The C-terminal section of growth hormone with potentiated fat-breakdown activity.
Fragment 176-191 is the isolated tail section of the human growth hormone molecule. It was researched to maximise the lipolytic properties of hGH without the accompanying effects on blood glucose.
The literature reports up to twelve-fold stronger stimulation of fat breakdown compared with the full hGH molecule, along with inhibition of fatty acid re-accumulation in adipocytes.
We do not currently stock this compound.
MOTS-c
A mitochondrial peptide — regulator of cellular energetics, studied as an “exercise mimetic”.
MOTS-c is a peptide encoded directly by mitochondrial DNA (an MDP). It acts as a signalling molecule between the mitochondrion and the cell nucleus and participates in regulating energy metabolism.
It sits at the centre of research into metabolic flexibility and insulin sensitivity. It is described as an exercise mimetic because it activates some of the pathways otherwise triggered by physical exertion.
View product →